Pirfenidone
- Generic Name
- Pirfenidone
- Brand Names
- Esbriet, Pirfenidone axunio (previously Pirfenidone AET), Pirfenidone Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C12H11NO
- CAS Number
- 53179-13-8
- Unique Ingredient Identifier
- D7NLD2JX7U
- Background
Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is proposed to primarily regulate tumor necro...
- Indication
Pirfenidone is indicated for the treatment of idiopathic pulmonary fibrosis (IPF). In Canada and Europe, it is approved in adults only.
- Associated Conditions
- Idiopathic Pulmonary Fibrosis (IPF), Mild Idiopathic Pulmonary Fibrosis, Moderate Idiopathic Pulmonary Fibrosis
- Associated Therapies
- -
A Study About Safety and Efficacy of Pirfenidone to Treat Grade 2 or Grade3 Radiation-induced Lung Injury.
- Conditions
- Interventions
- First Posted Date
- 2019-04-04
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
- Target Recruit Count
- 126
- Registration Number
- NCT03902509
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Efficacy and Safety of Pirfenidone in Patient With Dermatomyositis Interstitial Lung Disease (Dm-ILD)
- Conditions
- Interventions
- First Posted Date
- 2019-02-28
- Last Posted Date
- 2019-02-28
- Lead Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
- Target Recruit Count
- 152
- Registration Number
- NCT03857854
- Locations
- 🇨🇳
Zhang, Ling, Beijing, Beijing, China
Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung Disease
- Conditions
- Interventions
- First Posted Date
- 2019-02-27
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
- Target Recruit Count
- 144
- Registration Number
- NCT03856853
- Locations
- 🇨🇳
Zhang, Ling, Beijing, Beijing, China
Pilot Study of Pirfenidone in Pulmonary Fibrosis With Anti-myeloperoxydase Antibodies
- First Posted Date
- 2017-12-28
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 7
- Registration Number
- NCT03385668
- Locations
- 🇫🇷
Cochin Hospital, Paris, France
Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction
- Conditions
- Interventions
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 10
- Registration Number
- NCT03359863
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Pirfenidone for Progressive Fibrotic Sarcoidosis
- First Posted Date
- 2017-08-24
- Last Posted Date
- 2017-09-28
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 60
- Registration Number
- NCT03260556
- Locations
- 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
Non-Interventional Study (NIS) Collecting Experiences For IPF in Taiwan
- First Posted Date
- 2017-08-08
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 101
- Registration Number
- NCT03242759
- Locations
- 🇨🇳
Chang-Hua Christian Hospital, Changhua, Taiwan
🇨🇳Chang Gung Memorial Hospital(Linkou), Tao-Yuan, Taiwan
🇨🇳Taichung Veterans General Hospital, Taichung, Taiwan
Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF).
- First Posted Date
- 2017-07-06
- Last Posted Date
- 2020-11-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 60
- Registration Number
- NCT03208933
- Locations
- 🇷🇺
Regional State Budgetary Institution of Healthcare "Regional Cinilcal Hospital"; Pulmonology, Barnaul, Altaj, Russian Federation
🇷🇺Pulmonologii NII FMBA of Russia, Moscow, Moskovskaja Oblast, Russian Federation
🇷🇺Budget Institution of Healthcare of Voronezh Region "Voronezh Regional Clinical Hospital #1", Voronezh, Russian Federation
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
- First Posted Date
- 2017-06-06
- Last Posted Date
- 2024-11-27
- Target Recruit Count
- 48
- Registration Number
- NCT03177291
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Quality of Life Study in Participants With IPF Under Pirfenidone Treatment
- First Posted Date
- 2017-04-14
- Last Posted Date
- 2020-08-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 102
- Registration Number
- NCT03115619
- Locations
- 🇬🇷
University General Hospital of Ioannina, Ioannina, Greece
🇬🇷Sotiria Hospital for Diseases of the Chest, Academic Department of Pneumonology, Athens, Greece
🇬🇷University General Hospital of Athens "Attikon", B' University Pulmonary Clinic, Chaidari, Greece
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.